# Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis

> **NCT02220244** · PHASE3 · UNKNOWN · sponsor: **MedDay Pharmaceuticals SA** · enrollment: 105 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** MD1003 100mg capsule

## Key facts

- **NCT ID:** NCT02220244
- **Lead sponsor:** MedDay Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-10
- **Primary completion:** 2015-12
- **Final completion:** 2018-01
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2017-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02220244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02220244, "Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02220244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*